University of Pittsburgh
Pittsburgh, Pennsylvania, 15260, United States
NCT Number: NCT03305731
Stroke survivors demonstrate high levels of sedentary behavior, placing them at risk for exacerbation of chronic health conditions. This may lead to recurrent stroke. Subtle cognitive impairments are common after stroke and can lead to difficulty self-monitoring and problem solving to overcome barriers to physical activity. Investigators developed the Activating Behavior for Lasting Engagement (ABLE) intervention to promote activity scheduling, self-monitoring, and problem solving activity over the full day. This study examines the effects of the ABLE intervention on sedentary behavior after stroke.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Pittsburgh, Pennsylvania, 15260, United States
The study advisory committee added a dose-matched, no-intervention delayed baseline to the study protocol following initial documentation of this study protocol on clinicaltrials.gov. The purpose of this delayed baseline design was to assess the baseline stability on the primary and secondary outcomes. The addition of this timepoint resulted in a shift of post-intervention timepoints as follows: Baseline 1 (week 1), Baseline 2 (week 6), Post-intervention (week 11), and Follow-up (week 18). Intervention was delivered between Baseline 2 and Post-intervention.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Activating Behavior for Lasting Engagement (ABLE) is a behavioral intervention in which participants learn skills to schedule, self-monitor, and problem solve strategies to overcome barriers to engagement in meaningful daily life activities.
Time frame: Baseline (Baseline=computed mean of week 1 and week 6) to 11 weeks
Objectively measured sedentary time (ActivPAL)
Time frame: Baseline (Baseline=computed mean of week 1 and week 6) to 11 weeks
Objectively measured sedentary breaks (ActivPAL)
Time frame: Baseline (Baseline=computed mean of week 1 and week 6) to 18 weeks
Objectively measured sedentary breaks (ActivPAL)
Time frame: Baseline (Baseline=computed mean of week 1 and week 6) to 18 weeks
Objectively measured sedentary time (ActivPAL)
Time frame: Baseline (Baseline=computed mean of week 1 and week 6) to 11 weeks
Client rated participation in meaningful daily life activities using the Stroke Impact Scale - Participation Subscale
The Stroke Impact Scale - Participation Subscale is a questionnaire-based measure of community participation. Participants rate their participation in 10 types of activities on a 1 to 5 point Likert-type scale. Scores are converted to a 0 to 100 scale, where low scores indicate low participation.
Time frame: Baseline (Baseline=computed mean of week 1 and week 6) to 18 weeks
Client rated participation in meaningful daily life activities using the Stroke Impact Scale - Participation Subscale
The Stroke Impact Scale - Participation Subscale is a questionnaire-based measure of community participation. Participants rate their participation in 10 types of activities on a 1 to 5 point Likert-type scale. Scores are converted to a 0 to 100 scale, where low scores indicate low participation.
University of Pittsburgh
Other
Acronym: ABLE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00891514
Behavior, Brain Diseases
Baltimore, Maryland, United States
View Trial DetailsNCT06597929
Behavior, Brain Diseases
Barcelona, Catalonia, Spain
View Trial DetailsNCT04987255
Behavior, Brain Diseases
Geneva, Switzerland
View Trial DetailsNCT03632499
Behavior, Brain Diseases
Hammel, Denmark
View Trial Details